Avantika Medex Private Limited

Avantika Medex Private Limited, established on September 18, 2007, is a privately held pharmaceutical company headquartered in Ahmedabad, Gujarat, India. The company is registered under the Corporate Identification Number (CIN) U51397GJ2007PTC082606. As of the latest available data, Avantika Medex has an authorized capital of ₹5.00 crore and a paid-up capital of ₹3.03 crore. The company is led by directors Mr. Lal Babu Singh and Mrs. Vibha Rani Singh, who have been at the helm since its inception. Avantika Medex specializes in the manufacture, export, and wholesale distribution of pharmaceutical products, serving a diverse clientele across various international markets.

Avantika Medex operates a state-of-the-art manufacturing facility located at Gallops Industrial Park-2, Ahmedabad, Gujarat. This multifunctional plant, established in 2019, spans a plot area of 6,150 square meters with a built-up area of 4,055.53 square meters. The facility is EU-GMP and WHO-GMP certified, ensuring adherence to international quality standards. It is equipped with dedicated production lines for sachet filling, capsule filling, and semi-solid formulations, enabling the manufacture of a diverse range of products, including tablets (uncoated, coated, chewable, dispersible, sustained release), hard gelatin capsules, dry powder for sachets, and semi-solids like gels, creams, and ointments.

The leadership team at Avantika Medex is spearheaded by directors Mr. Lal Babu Singh and Mrs. Vibha Rani Singh, who have been instrumental in the company's growth and strategic direction since its establishment in 2007. Their combined experience and vision have been pivotal in positioning Avantika Medex as a reputable player in the pharmaceutical export sector.

Avantika Medex has made significant strides in expanding its presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds EU-GMP and WHO-GMP certifications, which are essential for market access in these regions. While specific regulatory filings and approvals in these markets are not publicly disclosed, the certifications indicate compliance with international standards, facilitating potential market entry. The company's strategic focus on quality and compliance positions it favorably for future regulatory approvals in these regions.

Avantika Medex has established a strong foothold in emerging markets across Africa, Latin America, and Southeast Asia. The company's products are tested in accordance with current testing requirements and comply with global norms, enhancing their appeal in these regions. Additionally, the EU-GMP and WHO-GMP certifications held by the manufacturing facility may facilitate access to markets that require such qualifications, potentially opening doors to further expansion in these emerging markets.

Avantika Medex's geographic strategy demonstrates a balanced approach, with a significant presence in both established and emerging markets. The company's focus on obtaining EU-GMP and WHO-GMP certifications reflects a commitment to meeting international standards, which is crucial for accessing regulated markets. Simultaneously, its expansion into emerging markets indicates a strategic diversification to mitigate risks associated with over-reliance on any single market. This approach suggests a well-rounded strategy aimed at sustainable growth and market resilience.

Specific details regarding Avantika Medex's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. However, the company's EU-GMP and WHO-GMP certifications suggest a commitment to adhering to international quality standards, which is a prerequisite for FDA approvals. The absence of publicly available FDA-specific information may indicate that the company is in the process of seeking FDA approvals or has not yet pursued them.

Avantika Medex's manufacturing facility holds both EU-GMP and WHO-GMP certifications, underscoring its adherence to stringent international quality standards. These certifications are critical for market access in various regions, including the European Union and countries that recognize WHO-GMP standards. The facility's compliance with these certifications reflects the company's commitment to producing high-quality pharmaceutical products that meet global norms.

Avantika Medex operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is EU-GMP and WHO-GMP certified, indicating compliance with international standards. While specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed, the company's adherence to global quality standards suggests a strong alignment with Indian regulatory requirements.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Avantika Medex. The absence of such records may indicate a clean regulatory history, reflecting the company's commitment to maintaining high-quality manufacturing practices. However, the lack of publicly available information also suggests that the company may not have pursued approvals in certain markets or that such information is not publicly accessible.

Avantika Medex operates in a competitive pharmaceutical export market, facing competition from both domestic and international companies. While specific competitors are not identified in the available data, the company's focus on obtaining EU-GMP and WHO-GMP certifications positions it favorably in the market. These certifications are recognized globally and can enhance the company's credibility and competitiveness. Additionally, Avantika Medex's strategic expansion into emerging markets may provide a competitive edge by tapping into regions with growing demand for pharmaceutical products.

Avantika Medex's key differentiators include its EU-GMP and WHO-GMP certified manufacturing facility, which ensures adherence to international quality standards. The company's diverse product portfolio, encompassing various pharmaceutical formulations, allows it to cater to a wide range of therapeutic needs. Additionally, Avantika Medex's strategic focus on both established and emerging markets demonstrates a balanced approach to growth and risk management.

Avantika Medex's current strategic direction emphasizes compliance with international quality standards, as evidenced by its EU-GMP and WHO-GMP certifications. The company's expansion into emerging markets indicates a focus on diversifying its market presence and reducing dependence on any single region. Looking ahead, Avantika Medex may consider pursuing regulatory approvals in additional markets, including the United States, to further enhance its global footprint.

Avantika Medex has demonstrated a consistent track record in pharmaceutical exports, with a total export value of $973,000 USD across 22 shipments. The company's product portfolio is concentrated, with the top five products accounting for 100% of exports. This concentration indicates a focused approach to product offerings. The company's adherence to EU-GMP and WHO-GMP standards suggests reliability and a commitment to quality, which are critical indicators for importers assessing potential suppliers.

Importers should verify the following certifications when considering Avantika Medex as a supplier:

• EU-GMP Certification: Confirms compliance with European Union Good Manufacturing Practices.

• WHO-GMP Certification: Indicates adherence to World Health Organization Good Manufacturing Practices.

• FDA Registration: If applicable, confirms registration with the U.S. Food and Drug Administration.

• ISO Certifications: Verify specific ISO certifications relevant to pharmaceutical manufacturing.

To verify these certifications, importers can request copies of the certificates directly from Avantika Medex or consult the issuing authorities' official websites for validation.

When conducting due diligence on Avantika Medex, importers should consider the following steps:

• Verify Certifications: Ensure that the company holds valid EU-GMP and WHO-GMP certifications.

• Assess Financial Stability: Review the company's financial statements to evaluate its financial health.

• Evaluate Product Quality: Request product samples and assess their quality against industry standards.

• Check Regulatory Compliance: Confirm that the company complies with relevant regulatory requirements in target markets.

• Review Export History: Examine the company's export records to assess consistency and reliability.

Red flags to watch for include expired or invalid certifications, inconsistent product quality, and a lack of transparency in financial and regulatory matters. Recommended pre-order checks involve conducting site visits, engaging with current clients for feedback, and consulting industry experts for insights into the company's reputation and reliability.